A Study of Improvement in Psoriasis Symptoms Associated With Combinations of Biologically Active Natural Substances (SFA-002) With Known Safety Profile
Latest Information Update: 11 Jan 2025
At a glance
- Drugs SFA 002 (Primary) ; Calcium; Magnesium; Propionates; Vitamin D
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors SFA Therapeutics
Most Recent Events
- 24 Dec 2024 Planned number of patients changed from 30 to 90.
- 24 Dec 2024 Planned End Date changed from 31 Jul 2024 to 31 Jul 2025.
- 24 Dec 2024 Planned primary completion date changed from 30 Jun 2024 to 30 Jul 2025.